Device Classification: The First and Most Critical Step

Over 14,200 foreign medical devices received NMPA registration certificates in the 2021–2025 period, with the Chinese medical device market reaching RMB 1.3 trillion (approximately USD 180 billion) in 2025, making it the second-largest medical device market globally. For foreign manufacturers seeking to enter or expand in this market, NMPA (National Medical Products Administration, 国家药品监督管理局, guójiā yàopǐn jiāndū guǎnlǐ jú) registration is the mandatory regulatory gateway — no device can be imported, sold, or distributed in China without a valid NMPA registration certificate. The 2026 regulatory framework, shaped by the 2022 amendments to the Regulations on the Supervision and Administration of Medical Devices (RSAMD, 医疗器械监督管理条例, yīliáo qìxiè jiāndū guǎnlǐ tiáolì) and the subsequent 2024–2025 implementing rules, introduced significant changes including streamlined quality management system (QMS) audits for low-risk devices, enhanced post-market surveillance obligations, and a new “Innovation Device” expedited pathway. This guide provides the complete step-by-step process for foreign manufacturers to register their medical devices with NMPA in 2026.

Device Classification: The First and Most Critical Step

China classifies medical devices into three categories based on risk level, following the Medical Device Classification Catalogue (医疗器械分类目录, yīliáo qìxiè fēnlèi mùlù), which was comprehensively revised in 2023 and updated annually. Classification determines the registration pathway, testing requirements, review timeline, and costs. Misclassification — even unintentional — can result in application rejection and a 6-month cooling-off period before reapplication.

Under the 2023 Classification Catalogue, over 900 new device types were added and 200 reclassified. As of 2026, approximately 12% of Class III applications received classification re-determination requests from the Center for Medical Device Evaluation (CMDE, 医疗器械技术审评中心, yīliáo qìxiè jìshù shěnpíng zhōngxīn). Foreign manufacturers uncertain about classification can submit a classification determination request (分类界定申请, fēnlèi jièdìng shēnqǐng) to CMDE, which provides a binding determination within 35 working days (RMB 10,000 processing fee).

Prerequisites: Documents and Preparations

Before initiating the NMPA registration process, manufacturers must prepare a comprehensive technical dossier. The requirements differ slightly between Class I (filing) and Class II/III (registration), but the core documentation package is consistent.

Foreign manufacturers must designate a Chinese Registered Agent — a legally registered entity in China responsible for communication with NMPA and post-market obligations. Under Article 14 of RSAMD (2022 revision), the Registered Agent bears joint liability for post-market adverse events. The agent must be a legal entity with a business scope covering medical device registration consulting or related services. (Source: NMPA Guidance on Registered Agent Responsibilities, 2025 Edition)

Step-by-Step NMPA Registration Process

The registration process for Class II and III medical devices follows a seven-step sequence. Class I devices follow a simplified filing procedure (steps 1, 4, and 7 only). The complete process typically takes 12–24 months for Class III devices and 8–14 months for Class II devices.

1. Determine Device Classification and Applicable Standards — Identify the correct classification code from the Medical Device Classification Catalogue. Compile a list of applicable mandatory standards (GB — national mandatory standards) and recommended standards (GB/T, YY, YY/T). Foreign manufacturers frequently underestimate the number of Chinese-specific standards — for example, China has over 40 YY standards specific to electromedical equipment that do not have direct IEC equivalents. Budget 4–6 weeks for comprehensive standards mapping. Engaging a local regulatory consultant with NMPA standards expertise (RMB 50,000–100,000) is strongly recommended.
2. Type Testing at NMPA-Accredited Laboratory — Submit device samples (typically 3–5 units plus accessories) to an NMPA-accredited testing laboratory (检验机构, jiǎnyàn jīgòu). As of 2026, there are 56 NMPA-accredited medical device testing laboratories in China, with the busiest being the Beijing Medical Device Testing Center (BMDTC) and Shanghai Medical Device Testing Institute (SMDTI). Test perimeters must cover all applicable GB and YY standards. Testing timeline: 4–8 weeks for Class II devices, 8–16 weeks for Class III devices depending on complexity and lab workload. Average cost: RMB 50,000–300,000 depending on device complexity and standards count. The 2026 revision allows parallel testing at multiple accredited labs for different standard subsets — a significant efficiency improvement over the previous sequential-only approach.
3. Clinical Evaluation Preparation — Prepare clinical evaluation data. Three pathways exist: (a) Chinese clinical trial (gold standard, required for most Class III implantable devices), (b) clinical evaluation via equivalent device (同品种医疗器械临床评价, tóng pǐnzhǒng yīliáo qìxiè línchuáng píngjià) — acceptable for Class II and some non-implantable Class III devices if sufficient scientific literature and existing clinical data support equivalence — and (c) exemption catalog (免于进行临床试验医疗器械目录, miǎn yú jìnxíng línchuáng shìyàn mùlù) — devices listed in the exemption catalog need no clinical evaluation. As of 2026, the exemption catalog covers approximately 2,800 device types. For devices requiring clinical trials, Chinese hospitals must be NMPA-certified GCP trial sites. Budget: RMB 500,000–5,000,000 for clinical trial costs depending on patient cohort size.
4. Dossier Submission to CMDE/Provincial NMPA — Submit the complete registration dossier via NMPA’s electronic submission system (eRPS system, 医疗器械注册电子申报系统). Class II devices are submitted to the provincial NMPA where the Registered Agent is located. Class III devices are submitted directly to CMDE (national level). The dossier must follow CMDE’s Format 80 (CTD-style) structure. Acceptance review takes 3–5 working days; incomplete dossiers are returned with a deficiency notice listing missing items. The acceptance rate on first submission for foreign devices was 68% in 2025, meaning 32% of applications were returned for completeness deficiencies.
5. Technical Review by CMDE — CMDE conducts a substantive technical review covering: product safety and performance (per PTR and standards), clinical evaluation adequacy, manufacturing quality system documentation, and label/instruction manual compliance. CMDE may issue 1–3 rounds of supplemental queries (补充资料通知单, bǔchōng zīliào tōngzhī dān). Response time: 40 working days per query. Average Class III review cycle: 8–14 months including query response time. Devices designated as “Innovation Medical Device” (创新医疗器械, chuàngxīn yīliáo qìxiè) — as of 2026, approximately 420 devices have received this designation — qualify for priority review with a target of 60 working days. Innovation designation requires demonstrating (a) the device has a patent in China, (b) it represents a significant technological advancement, and (c) it has clear clinical advantages for Chinese patients.
6. QMS Audit (Manufacturing Site Inspection) — For Class II and III devices, NMPA conducts a quality management system audit of the manufacturing facility. Foreign manufacturers may qualify for a reduced-scope audit if they hold a current MDSAP certificate (Medical Device Single Audit Program). The audit covers ISO 13485 compliance plus China-specific GMP requirements as defined by the Medical Device GMP (医疗器械生产质量管理规范, yīliáo qìxiè shēngchǎn zhìliàng guǎnlǐ guīfàn). Audit timeline: 3–5 days on-site; travel and logistics arranged by the manufacturer. NMPA typically schedules foreign factory audits 2–4 months after technical review completion. Under the 2025 “Paperless Audit” pilot program, manufacturers with a 3-year clean audit history may qualify for a remote document review instead of on-site inspection. As of mid-2026, 45 foreign manufacturers have qualified for paperless audits, reducing audit costs by approximately 60%.
7. Registration Certificate Issuance and Post-Market Obligations — Upon successful completion of technical review and QMS audit, NMPA issues the Medical Device Registration Certificate (医疗器械注册证, yīliáo qìxiè zhùcè zhèng), valid for 5 years. The certificate must be renewed at least 6 months before expiry. Post-market obligations include: adverse event reporting within 20 working days of occurrence (Article 72, RSAMD), annual product quality summary reports, and immediate recall obligations for safety defects under the Medical Device Recall Management Provisions (2023 revision).

Costs and Budget Considerations

NMPA medical device registration costs vary dramatically by classification, device complexity, and the extent of testing and clinical data required. Below is a realistic budget breakdown for a typical Class III implantable device versus a Class II non-invasive device.

According to the China Medical Device Industry Association (CMDI, 中国医疗器械行业协会) 2025 Annual Report, the average total cost for a foreign manufacturer to register a Class III device in China was RMB 3.2 million (approximately USD 442,000), with Class II averaging RMB 780,000 (approximately USD 108,000). The 2022–2025 regulatory reforms, particularly the expanded clinical evaluation exemption catalog and the acceptance of overseas clinical data per ICH E17, have reduced costs by an estimated 15–20% compared to pre-2022 levels.

Common Pitfalls and How to Avoid Them

• Treating ISO 13485 Certification as Sufficient for QMS Compliance — The NMPA’s Medical Device GMP (2014 edition with 2022 amendments) includes requirements beyond ISO 13485, specifically: Chinese-language quality manuals and procedures, a designated Chinese management representative, and stricter requirements for supplier management (including mandatory on-site audits of critical suppliers in China). Even manufacturers with robust ISO 13485 systems fail NMPA QMS audits if these China-specific elements are absent.
• Ignoring Chinese-Specific Electromagnetic Compatibility (EMC) Requirements — China’s EMC standards (YY 9706.102-2021) have deviated from their IEC 60601-1-2 base in critical areas, including stricter radiated emissions limits in the 30–230 MHz band and mandatory surge immunity tests for all Class II and III devices. Devices that passed EU/UKCA EMC testing frequently require redesign for the Chinese market. Budget for additional EMC testing and possible hardware modifications.
• Assuming the Exemption Catalog Is Static — The clinical evaluation exemption catalog is updated annually, and devices are sometimes removed. In the 2025 update, 14 Class II device types were removed from the exemption catalog and now require clinical evaluation. Check the most current catalog — as of July 2026, version 2026-1 is in effect — before finalizing your regulatory strategy.
• Underestimating Renewal Timelines — Registration certificates are valid for 5 years, but renewal applications must be submitted at least 6 months before expiry. The 2024 procedures require a full re-evaluation of the device against current standards, which may have changed since the original registration. If standards have changed, additional type testing is required. For Class III devices, allow 12–18 months for the renewal process — significantly longer than many manufacturers assume.
• Neglecting UDI Compliance — China’s Unique Device Identification (UDI) system, mandated under the 2023 Provisions on UDI Management, requires Class II devices to bear a UDI code by January 1, 2025 and Class III devices by January 1, 2024. The UDI database (中国医疗器械唯一标识数据库, zhōngguó yīliáo qìxiè wéiyī biāoshí shùjùkù) is administered by NMPA and requires registration of each device model and batch. Non-compliant devices cannot be distributed, even if they hold a valid registration certificate.

Post-Registration Commercialization and Market Access

After obtaining the NMPA registration certificate, foreign manufacturers must complete several additional steps before commercial distribution: (1) obtain a Medical Device Import Record Certificate from China Customs (requires registration certificate plus free sale certificate), (2) register with the China Medical Device Supply Chain Platform (药械集中采购平台, yào xiè jízhōng cǎigòu píngtái) for hospital procurement eligibility — mandatory for all inpatient devices, (3) negotiate provincial-level tenders for Class II and III devices (各省医用耗材集中采购, gè shěng yīyòng hàocái jízhōng cǎigòu) — pricing and volume vary significantly by province, and (4) establish a local service entity or contract with an authorized service provider for in-China technical support and maintenance. Clinical hospital adoption typically requires 6–18 months post-registration, including product evaluation, hospital formulary committee approval, and procurement system registration.

Where to Go From Here

Based on what you just read:

• Ready to act? Read [guide: NMPA-medical-device-registration-checklist]
• Still comparing? See [comparison: NMPA-vs-FDA-vs-CE-marking-pathways]
• Need numbers? Try [tool: medical-device-registration-cost-calculator]

— China Gateway 360 —
Remote China market entry support, built around execution.